The Beauty Health Company (SKIN) Q4 2024 earnings summary

Executive summary

• Full-year net revenue was $334.3 million, with adjusted EBITDA of $12.3 million, both exceeding guidance despite a challenging macro environment and significant decline in equipment sales.

• Transformation efforts included cost optimization, operational stabilization, and a focus on innovation and commercial execution, resulting in improved gross margin and profitability.

• Net loss for Q4 2024 was $10.3 million, flat year-over-year; full year net loss improved to $29.1 million from $100.1 million in 2023, mainly due to absence of prior year Syndeo Program charges.

• Strategic priorities included sales execution, operational excellence, and financial discipline, with a new commercial leadership team and enhanced go-to-market model.

• Active install base grew to 34,735 units, up from 31,446, despite fewer new system placements.

Financial highlights

• Q4 2024 net sales were $83.5 million, down 13.8% year-over-year, with global equipment sales declining 40% but consumable sales up 8.7%.

• Full-year consumable sales reached $208.9 million, up from $191.4 million, with growth in all regions.

• Q4 adjusted gross margin improved to 67.1% from 54.6% year-over-year; GAAP gross margin was 62.7%.

• Q4 adjusted EBITDA was $9.0 million (10.8% margin), up from $3.4 million (3.5% margin) in Q4 2023; full year adjusted EBITDA was $12.3 million (3.7% margin).

• Ended the year with $370 million in cash after repurchasing $192 million of convertible debt.

Outlook and guidance

• FY 2025 net sales guidance is $270–$300 million, with adjusted EBITDA expected between $10–$25 million.

• Q1 2025 net sales expected at $61–$66 million, with adjusted EBITDA between $(6)–$(4) million.

• Capital expenditures for 2025 expected to be $10–$15 million.

• Guidance assumes continued pressure on delivery systems sales and no material deterioration in market conditions.